A phase 1/2 trial of Personalized Neoantigen Peptide Vaccine in advanced solid tumours, run by Seqker Biosciences, Inc., now recruiting.
Personalized Neoantigen Peptide Vaccines for Solid Tumors is a phase 1/2 interventional study registered as NCT07002203 by Seqker Biosciences, Inc., with 10 participants planned, started 2024-03-01 and due to reach its primary completion in 2027-08. Interventions recorded: Personalized Neoantigen Peptide Vaccine.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.